Related Experiment Video
Updated: Jun 6, 2026
09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
[Relationship between cyclooxysenase 2 and serious hepatitis].
Ma Dong-rui1, Yuan Dong-hong, Xie Hua-hong
1Department of Gasteroenterology, Yanan University, Xi'an, China.
Summary
Serum levels of TXB2 and 6-keto-PGF1α, products of cyclooxygenase-2 (COX-2), are elevated in serious hepatitis. The TXB2/6-keto-PGF1α ratio serves as a diagnostic marker for hepatitis B virus-associated liver disease.
Area of Science:
- Hepatology
- Biochemistry
- Immunology
Context:
- Hepatitis B virus (HBV)-associated serious liver disease poses a significant global health challenge.
- Understanding the molecular mechanisms driving hepatitis progression is crucial for developing effective treatments.
Purpose:
- This study aimed to investigate the role of cyclooxygenase-2 (COX-2) in serious hepatitis.
- The research focused on evaluating the downstream effects of COX-2 on cytokine regulation and their association with disease progression.
Summary:
- Serum levels of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (6-keto-PGF1α), metabolites of COX-2, were significantly elevated in patients with serious hepatitis compared to individuals with general HBV infection.
- These elevated levels were observed across acute, sub-acute, and chronic forms of serious hepatitis, though no significant differences were found among these subtypes.
- The TXB2/6-keto-PGF1α ratio emerged as a potential effective biological marker for the prognosis and diagnosis of serious hepatitis.
Impact:
- The findings highlight the involvement of COX-2 metabolic products in the pathogenesis of serious hepatitis.
- The TXB2/6-keto-PGF1α ratio shows promise as a valuable biomarker for clinical management and patient stratification in serious hepatitis.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:17Gastritis-II: Pathophysiology
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...